A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 432
- Population
- ALL · 50 Years
- Duration
- 2023-03-14 to 2025-12-29
- Intervention
- RC28-E; Aflibercept
- Comparator
- Aflibercept
- Outcomes measured
- Mean change from baseline in BCVA at week 48; — Baseline, week 48; Average change in BCVA from baseline over the period week 36 through week 48; — Baseline, weeks 36, 40, 44 and 48.; Proportion of subjects with q12w injection; — Baseline, week 48; Proportion of subjects with q12w injection at week 48 within the subjects with no q8w injection need at week 16, week 2…; Proportion of subjects with gain in BCVA of 15/10/5/0 letters or more from baseline to week 48; — Baseline, week 48; Mean change in CST from baseline to week 16, week 48; — Baseline, week 16, 48; Average change in CST from baseline over the period week 36 through week 48; — Baseline, weeks 36, 40, 44 and 48.; Proportion of subjects with presence of intraretinal fluid/subretinal fluid at week 16, week 48; — Baseline, week 16, 48; Percentage of subjects with disease activity present at week 16; — Baseline, week 16; Change in choroidal neovascularization (CNV) lesion size from baseline to week 12, week 48; — Baseline, week 12, 48; Proportion of subjects with q8w treatment need at weeks 16, 20, 28, 32, 40, 44; — Weeks 16, 20, 28, 32, 40, 44; Incidence and characteristics of ocular and systemic treatment emergent adverse events. — Baseline, week 48
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.